Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis

被引:636
作者
Singh, Sonal
Loke, Yoon K.
Furberg, Curt D.
机构
[1] Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
[3] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 298卷 / 10期
关键词
D O I
10.1001/jama.298.10.1189
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Recent reports of serious adverse events with rosiglitazone use have raised questions about whether the evidence of harm justifies its use for treatment of type 2 diabetes. Objective To systematically review the long-term cardiovascular risks of rosiglitazone, including myocardial infarction, heart failure, and cardiovascular mortality. Data Sources We searched MEDLINE, the GlaxoSmithKline clinical trials register, the US Food and Drug Administration Web site, and product information sheets for randomized controlled trials, systematic reviews, and meta-analyses published in English through May 2007. Study Selection Studies were selected for inclusion if they were randomized controlled trials of rosiglitazone for prevention or treatment of type 2 diabetes, had at least 12 months of follow-up, and monitored cardiovascular adverse events and provided numerical data on all adverse events. Four studies were included after detailed screening of 140 trials for cardiovascular events. Data Extraction Relative risks (RRs) of myocardial infarction, heart failure, and cardiovascular mortality were estimated using a fixed-effects meta-analysis of 4 randomized controlled trials (n = 14 291, including 6421 receiving rosiglitazone and 7870 receiving control therapy, with a duration of follow-up of 1-4 years). Results Rosiglitazone significantly increased the risk of myocardial infarction (n = 94/6421 vs 83/7870; RR, 1.42; 95% confidence interval [CI], 1.06-1.91; P = .02) and heart failure (n = 102/6421 vs 62/7870; RR, 2.09; 95% CI, 1.52-2.88; P < .001) without a significant increase in risk of cardiovascular mortality (n = 59/6421 vs 72/7870; RR, 0.90; 95% CI, 0.63-1.26; P = .53). There was no evidence of substantial heterogeneity among the trials for these end points (I-2 = 0% for myocardial infarction, 18% for heart failure, and 0% for cardiovascular mortality). Conclusion Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantly increased risk of cardiovascular mortality.
引用
收藏
页码:1189 / 1195
页数:7
相关论文
共 26 条
[1]  
[Anonymous], COCHRANE HDB SYSTEMA
[2]  
BOLEN S, 2007, ANN INTERN MED 0716
[3]   Simpson's paradox and calculation of number needed to treat from [J].
Cates C.J. .
BMC Medical Research Methodology, 2 (1) :1-4
[4]   A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors [J].
Chiquette, E ;
Ramirez, G ;
DeFronzo, R .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (19) :2097-2104
[5]   A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure [J].
Dargie, Henry J. ;
Hildebrandt, Per R. ;
Riegger, Guenter A. J. ;
McMurray, John J. V. ;
McMorn, Stephen O. ;
Roberts, Jeremy N. ;
Zambanini, Andrew ;
Wilding, John P. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (16) :1696-1704
[6]   Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia [J].
Deeg, Mark A. ;
Buse, John B. ;
Goldberg, Ronald B. ;
Kendall, David M. ;
Zagar, Anthony J. ;
Jacober, Scott J. ;
Khan, Mehmood A. ;
Perez, Alfonzo T. ;
Tan, Meng H. .
DIABETES CARE, 2007, 30 (10) :2458-2464
[7]  
*DIV MET END PROD, 2007, FDA BRIEF DOC JOINT
[8]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[9]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[10]  
*GLAXOSMITHKLINE, 2006, HUM RAC ANN REP, P31